DocDollars

Amphastar Pharmaceuticals, Inc.

CA · United States · Reporting entity ID 100000000273

Total reported 2019–2025
$24.5M
#283 of 2,960 reporting companies — 0% of all reported industry payments
$107K in general payments across 4,872 records, plus $24.4M in research funding across 155 records.

How it breaks down

General payments $107,034
Research funding $24,363,428

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Amphastar Pharmaceuticals, Inc. reported $24.5M to US doctors and teaching hospitals from 2019 to 2025, ranking #283 of 2,960 reporting companies. 100% of that was research funding and 0% general payments such as consulting, speaking, food and travel. 4,872 general payment records and 155 research records were filed.

Common questions about Amphastar Pharmaceuticals, Inc.

How much has Amphastar Pharmaceuticals, Inc. paid US doctors?

Amphastar Pharmaceuticals, Inc. reported $24,470,463 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $107,034 in general payments, $24,363,428 in research funding.

How does Amphastar Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #283 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Amphastar Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.